<DOC>
	<DOCNO>NCT00096694</DOCNO>
	<brief_summary>Oral contraceptive ( OCs ) good option HIV infect woman potential drug interaction OCs anti-HIV drug ; additionally , OCs may increase risk transmit HIV sexual partner . Levonorgestrel commonly prescribe part combination OC . An intrauterine device ( IUD ) device insert woman 's uterus prevent pregnancy . The purpose study determine effect levonorgestrel-releasing IUD amount HIV present HIV infect woman 's cervix 4 week IUD use . Study hypothesis : There increase genital tract HIV RNA DNA placement levonorgestrel IUD .</brief_summary>
	<brief_title>Effect Intrauterine Contraceptive Device ( IUD ) HIV Infected Women</brief_title>
	<detailed_description>HIV infect woman face challenge prevent pregnancy HIV transmission sexual partner . However , OCs may interact antiretroviral therapy ( ART ) , data suggest high dos OCs may increase cervical shed HIV-1 , may increase HIV infected woman 's infectiousness sexual partner . A physical barrier contraceptive would useful HIV infected woman circumvent problem associate concurrent use OCs ART . The levonorgestrel IUD prove highly effective preventing unwanted pregnancy HIV uninfected woman since introduction United States 1999 . This study evaluate effect levonorgestrel IUD HIV viral load HIV infect woman 's cervix 4 week IUD use . This study last approximately 48 week ; 4 study visit . At screen , participant undergo medical medication history assessment ; complete physical exam ; pelvic exam , include genital tract sample collection ; blood collection ; sexually transmit disease ( STD ) testing ; Pap smear , need . The levonorgestrel IUD insert participant 's uterus study entry . At study entry Weeks 4 , 16 , 48 , participant undergo targeted physical exam ; pelvic exam , include genital tract sample collection ; blood collection . Participants give menstrual diary start study study visit ask document menstrual cycle duration study . To eligible study , participant may ART within 90 day prior study entry . However , Week 4 study visit , participant may reinitiate ( ART 90 day prior study entry ) initiate ( ART naive ) ART , deem necessary physician .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>HIV infect Willing able delay initiation reinitiation antiretroviral therapy Week 4 study visit Unlikely develop clinical indication start antiretroviral therapy within 4 week study entry CD4 count 200 cells/mm3 Viral load 10,000 copies/ml within 90 day prior study entry Endocervical viral load 2,500 copies/ml within 90 day prior study entry History prior pregnancy last least 20 week Willing continue current use hormonal contraceptive , except medroxyprogesterone acetate , Week 4 study visit Start last menstrual period within 7 day prior study entry Antiretroviral medication within 90 day prior study entry AIDS diagnosis , include CD4 count le 200 cells/mm3 Cervicitis , bacterial vaginosis , trichomoniasis , symptomatic vaginal candidiasis within 90 day prior study entry . Participants infection within 90 day prior study entry exclude received appropriate treatment document resolution infection . Acute history pelvic inflammatory disease , chlamydia , gonorrhea year prior study entry Abnormal Pap smear require treatment year prior study entry History ectopic pregnancy condition would predispose participant ectopic pregnancy Known uterine anomaly , include fibroid Known suspect breast cancer Acute liver disease liver tumor Have previously insert IUD remove Fungal infection genitals Genital bleed unknown cause Endometritis infect abortion within 90 day study entry Known allergy hypersensitivity component IUD use study Current drug alcohol abuse , opinion investigator , may interfere study Serious infection serious medical illness potentially life threaten require systemic therapy hospitalization within 14 day study entry Use etonogestrel ethinyl estradiol vaginal ring ( NuvaRing ) within 30 day prior study entry Medroxyprogesterone acetate within 90 day prior study entry Pregnant breastfeeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Intrauterine Device</keyword>
	<keyword>IUD</keyword>
	<keyword>Contraceptive</keyword>
	<keyword>Levonorgestrel</keyword>
</DOC>